Solriamfetol for the Treatment of Excessive Sleepiness in OSA [PDF]
Chest, 2019 International audience ; Background: Excessive sleepiness (ES) is a common symptom of OSA, which often persists despite primary OSA therapy. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of ES in adults with OSA.Methods: After 2 weeks of clinical titration (n = 174) and 2 weeks of stable dose ...
Patrick J. Strollo +39 more
openaire +2 more sources
A Review of a Recent Meta-Analysis Study on Obstructive Sleep Apnea [PDF]
, 2022 This paper summarizes a recent meta-analysis of various topics in obstructive sleep apnea (OSA). In addition to cardiovascular disease and neurocognitive dysfunction, a wide variety of diseases have been associated with OSA, and associations with cancer ...
Bo Yoon Choi, Jae Hoon Cho, Jin Kook Kim
core +1 more source
Narcolepsy Treatment: Present and Future [PDF]
, 2021 Narcolepsy is a chronic, disabling sleep disorder with a significant diagnostic delay. Nowadays, treatment is focused on managing symptoms that impacts patient’s life, such as at workplace, social events or even at school, but not aimed cure the disease.
Gabás, Patricia Ortega +6 more
core +2 more sources
Solriamfetol enhances alertness and cognitive performance in mice
AbstractSolriamfetol [(R)-2-amino-3-phenylpropylcarbamate hydrochloride], a phenylalanine derivative initially developed as potential antidepressant, was shown by our group in 2009 to have potent, dose-dependent wake-promoting activity in mice. Solriamfetol (Sunosi®) is used since 2019 to counteract excessive daytime sleepiness (EDS) in patients with ...
Haddar M +4 more
europepmc +2 more sources
The effect of therapy on arousal from sleep in patients with respiratory sleep disorders [PDF]
, 2022 Vibrotactile positional therapy (PT) is a relatively new treatment for positional obstructive sleep apnoea (POSA). It uses vibrotactile stimulus to encourage the sleeper to change position when supine.
Alqarni, Abdullah Saad
core +1 more source
Exploring Addictive Online Behaviors in Patients with Narcolepsy Type 1 [PDF]
, 2022 Background: Narcolepsy type 1 (NT1) is a rare neurological sleep disorder caused by the loss of neurons that produce hypocretin—a peptide that plays a crucial role in addictive behaviors.
Castelnuovo G. +8 more
core +6 more sources
A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness. [PDF]
Psychopharmacol BullPurpose of Review This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this ...
Fuller MC +10 more
europepmc +3 more sources
Depressive disorders: systematic review of approved psychiatric medications (2009-April 2025) and pipeline phase 3 medications. [PDF]
BMC PsychiatryBackgroundDepressive disorders remain a significant public health concern, with substantial personal, social, and economic impacts worldwide. The purpose of this systematic review is to examine the psychiatric medications approved by the FDA from 2009 ...
IsHak WW +15 more
europepmc +3 more sources
Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report [PDF]
, 2020 We describe a case of a young male patient with narcolepsy type 1 (NT1), who developed generalized cataplexy attacks during sexual intercourses, on which we have obtained a satisfactory control with pitolisant.
Dolso, Pierluigi +3 more
core +1 more source
0751 Epworth Sleepiness Scale Test-Retest Reliability Analysis In Solriamfetol Studies [PDF]
Sleep, 2020 Abstract Introduction The Epworth Sleepiness Scale (ESS) measures excessive daytime sleepiness. This analysis examined test-retest reliability of ESS scores in participants with narcolepsy or obstructive sleep apnea (OSA) in solriamfetol studies ...
J Black +6 more
openaire +1 more source